A B S T R A C T To elucidate the role of proteinase inhibitors in the regulation of protein breakdown in vivo, we measured the effect of leupeptin on the rate of appearance of leucine in the plasma compartment in overnight-fasted conscious dogs. Two groups of dogs were studied. The control group (I) received saline infusion, and the experimental group (II) was rendered hypercatabolic with daily administration of adrenocorticotropic hormone (ACTH) (500 U/d) for 4 d.
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ACTH treatment increased plasma cortisol from 2±0.4 to 17±2 Asg/dl (P < 0.005). It raised plasma leucine levels (jsmol/liter) from 123±6 in I to 206±5
in II (P < 0.01) and its rate of appearance into the plasma compartment (micromoles per kilogram per minute) from 3.1±0.1 in I to 4.6±0.3 in II (P < 0.01). Whole blood alanine concentration (micromoles per liter) increased by 50% (from 387±31 to 577±53, P < 0.01) and whole blood glutamine concentration (micromoles per liter) increased from 653±51 to 917±93 (P < 0.01). Leupeptin infusion in the ACTHtreated group significantly decreased both the concentration of plasma leucine and its rate of appearance. Blood glutamine declined by 30% (P < 0.05) after leupeptin, but no effect on blood alanine was observed.
Leupeptin had no effect on the saline control group. These data indicate that leupeptin decreases the accelerated rate of protein breakdown induced by cortisol excess. The fact that it did not affect protein deg-INTRODUCTION Protein degradation is a selective, energy-requiring process necessary for basic cellular function. It provides amino acids for synthesis of new proteins and clears the cells of abnormal proteins (1) . Most evidence suggests that the majority of long-lived intracellular proteins are degraded within lysosomes. This degradation is subject to hormonal and nutritional control. In contrast, the degradation of short-lived and abnormal proteins occurs in nonlysosomal fractions and is unresponsive to physiologic regulators (2) .
Recent reports have shown that the use of microbial proteinase inhibitors decreases the degradation of long-lived proteins in cultured hepatocytes (3) and in perfused rat livers deprived of substrates or insulin (2). They have also been shown to inhibit protein breakdown in isolated rat skeletal and heart muscle (4), and can slow the accelerated muscle proteolysis seen in dystrophic chicks (5) .
This study was performed to test the possibility of using microbial proteinase inhibitors to decrease the accelerated catabolism that accompanies various clinical conditions. We measured the effect of leupeptin on qualitative rates of protein breakdown in the con- (6) . On the day of the study the catheters were removed from the subcutaneous pockets through skin incisions made under local anesthesia. Angiocatheters (18 gauge) were inserted percutaneously into the two cephalic veins. These were used for isotope, hormone, or saline infusions. After this preparation, the conscious dogs were then placed in a Pavlov harness and allowed to rest for -1 h before beginning the intravenous infusion of the [3H]leucine. Experimental design. Two types of studies were performed. One group of animals (n = 10) received a 4-d pretreatment with ACTH (500 U i.m./d), while the rest (n = 8) received saline injections. After an 18-h overnight fast, all animals received a 7.5 h infusion of L-4,5,[3H]leucine for the measurement of plasma leucine kinetics. After a 3-h isotopic equilibration period and a 0.5-h basal period, five ACTH-treated and four untreated dogs received a continuous intravenous infusion of leupeptin (a mixture of propionyl-and acetyl-leucyl-leucyl-arginal) at 4.3 mg/min for a 4-h experimental period. The rest received saline. Blood samples were obtained at 10-min intervals during the basal period and at 30-min intervals during the experimental period. The collection and immediate processing of blood samples have been previously described (6) . Plasma immunoreactive glucagon was assayed with Unger's 30,000-mol wt antibody (7) , insulin with the Sephadex-bound antibody procedure (Pharmacia Fine Chemicals, Piscataway, NJ) (8) , and cortisol with radioimmunoassay (9) . The radioactivity and concentration of plasma leucine were determined by rapid column chromatography (6) . The specific radioactivity of [3H]leucine in the infusate solution was checked in each experiment in a similar fashion to the plasma samples. The coefficient of variation in duplicate pairs (n = 16) was 2.1% for arterial plasma concentration and 2.8% for leucine-specific activity (6) . Blood alanine and glutamine were determined enzymatically (10, 11) .
Tracer methods and calculations. At steady-state conditions, the rate of appearance of leucine into the plasma compartment was estimated by dividing the rate of isotope infusion (disintegrations per minute per kilogram) by the plateau arterial specific activity (disintegrations per minute per micromole per 103). During nonsteady-state conditions, calculation of the rate was carried out according to the method of Wall et al. (12) , used for determination of glucose production. This model assumes that rapid changes in leucine-specific activity and concentration do not occur uniformly within the entire pool. It also assumes that plasma reentry of isotope from the protein pool is negligible during the infusion period. Since the studies were done in the postabsorptive period, in the absence of exogenous leucine, the rate of appearance of this essential amino acid reflects the rate of protein breakdown (6) . Since the intracellular specific activity of [3Hlleucine is lower than that in plasma (13), a rate of appearance calculated using plasma specific activity will underestimate the total rate of protein degradation. Despite these limitations, changes in leucine rate of appearance in the plasma compartment should reflect any increase or decrease in the rate of protein breakdown (6) . Table I summarizes the mean hormonal values in the four groups. ACTH treatment resulted in a ninefold elevation in plasma cortisol (P < 0.001) without a change in plasma insulin or glucagon. Leupeptin exerted no effect on the hormonal levels throughout the study period.
RESULTS
The rate of appearance of leucine during the post- 5 , and after an 18 h of overnight fast, the ACTH-treated group received a constant intravenous infusion of ACTH (1 U/min) for 7.5 h, while the others received saline. During the experimental period (0-240 min) four dogs of the saline-infused group (saline + leupeptin) and five dogs of the ACTH-treated group (ACTH + leupeptin) received a continuous infusion of leupeptin (4.3 mg/min), while the other dogs served as controls. Analyses of variance during the basal period showed that ACTH treatment resulted in significantly higher leucine rates of appearance than in saline group (P < 0.01). Leupeptin resulted in significant reduction in the rate of appearance only in the ACTH-treated group (P < 0.01).
absorptive control period was 70% greater in the ACTH-treated dogs than in untreated dogs (Fig. 1) . This increased rate of appearance was associated with a 68% increase in the plasma concentration of leucine (Fig. 2) . In response to ACTH treatment, blood alanine rose by 53% (from 387±31 to 591±64 ,umol/liter, P < 0.05) and glutamine rose by 40% (from 653±51 to 917±93,umol/liter, P < 0.05).
In ACTH-treated animals, leupeptin caused a prompt and progressive fall in the rate of appearance of leucine, so that by the end of the experiment it did not differ significantly from that of the control animals. The plasma concentration of leucine fell concurrently, although it remained significantly elevated after 240 min. Leupeptin decreased blood glutamine by 30% (to 689±98 ztmol/liter, P < 0.05), as shown in Table  I . In sharp contrast, leupeptin had no effect on untreated animals. Both leucine rate of appearance and plasma concentration as well as blood glutamine and alanine remained constant throughout the entire 4-h period.
DISCUSSION
It is well known that glucocorticoid hormones promote the net release of amino acids from muscle by decreasing protein synthesis (14, 15) . Their effect on protein breakdown, however, remains controversial. Hopgood et al. (16) have recently shown that glucocorticoids enhance degradation by 10% as a result of increased autophagic activity in hepatocyte monolayers. Goldberg (17) and Tomas et al. (18) 2 The effect of leupeptin and ACTH on arterial plasma leucine in overnight-fasted dogs. The experimental design is outlined in Fig. 1 . Analyses of variance during the basal period showed that ACTH resulted in significantly higher leucine levels (P < 0.01). Leupeptin infusion resulted in marked reduction in leucine concentrations in the ACTH-treated group (P < 0.01). L, liter. doses of glucocorticoids. Other investigators (14, 15) failed to show increased protein breakdown after glucocorticoids even though they observed depression of protein synthesis. In this study, the 70% increase in the rate of appearance of leucine in plasma represents a minimum estimate, since intracellular specific activity may be lower than plasma. Since the studies were performed in the absence of exogenous intake of leucine, the accelerated appearance must have been from protein degradation and indicates that proteolysis must have increased by at least 70%.
Protein breakdown can involve lysosomal and nonlysosomal mechanisms. Lysosomal involvement in certain aspects of protein breakdown has been documented. Using perfused rat liver, Mortimore (2) presented compelling evidence for lysosomal participation in deprivation-enhanced protein breakdown and to a lesser degree in basal or steady-state protein turnover. Nonlysosomal mechanisms of protein breakdown are not yet clearly defined. Reticulocytes possess a nonlysosomal ATP-dependent system for protein breakdown with several essential components including the universally occurring polypeptide, ubiquitin (19) . This system is responsible for the rapid hydrolysis of abnormal hemoglobin (19) . In other cells, the biologic function of nonlysosomal proteolysis is not well understood, but may be related to the degradation of the short-lived proteins (2) .
Muscle preparations obtained from glucocorticoidtreated rats show dramatic increases in both cathepsin B and alkaline myofibrillar proteinase activities (20) , implicating these enzymes in increased proteolysis. Leupeptin has been shown to exert 80-85% of its activity against the lysosomal cathepsins B1, H, and L (21); it has also been shown to be effective against calcium-activated protease in cytoplasm of all cells (22) . In vivo, leupeptin has been shown to inhibit accelerated muscle proteolysis in dystrophic chicks (5) and to delay denervation atrophy of chicken pectoralis muscles (5 
